← Leaderboards
Robert J Matusik
Vanderbilt University
$12,749,356
Attributed
$12,861,129
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$12,861,129 · 8
By mechanism
R01$12,055,114 · 4
U54$806,015 · 4
Top collaborators
- Lynn M Matrisian4 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Douglas William Strand$6,322,171
- Lynn M Matrisian$19,522,211
- Susan Kasper$2,908,555
Others in their field
Top investigators on “Androgens”
- Shalendar Bhasin · La Biomed Res Inst/ Harbor Ucla Med Ctr$36,153,267
- Charles L Sawyers · Sloan-Kettering Inst Can Research$24,511,314
- Susan E. Hankinson · University Of Massachusetts Amherst$24,278,267
- Brian E Henderson · University Of Southern California$20,677,861
- Cory Abate-Shen · Columbia University Health Sciences$20,094,849
- Diane E Merry · Thomas Jefferson University$17,810,180
Research focus
AndrogensProstateGene ExpressionMalignant Neoplasm Of ProstateRegulationMolecularGenesProstaticAndrogen ReceptorCellsTranscription FactorPathway InteractionsIn VitroGrowthAmericanPlayResistanceResponseMalignant NeoplasmsProteinsReceptor SignalingCancer PatientReportingTumor Progression
Grant awards (49)
Project 2: Fetuin-A in Prostate Cancer$70,820
U54 · FY2023 · CA · contact PI
Project 2: Fetuin-A in Prostate Cancer$107,931
U54 · FY2022 · CA · contact PI
Project 2: Fetuin-A in Prostate Cancer$72,264
U54 · FY2021 · CA · contact PI
The NF-KappaB-Androgen Receptor Axis Drives Failure of Medical Therapy in Human Benign Prostatic Hyperplasia$402,692
R01 · FY2020 · DK · contact PI
Novel mechanisms of SKP2 and AR signaling on the suppression of prostate cancer$11,881
U54 · FY2020 · CA · contact PI
The NF-KappaB-Androgen Receptor Axis Drives Failure of Medical Therapy in Human Benign Prostatic Hyperplasia$402,692
R01 · FY2019 · DK · contact PI
Novel mechanisms of SKP2 and AR signaling on the suppression of prostate cancer$8,158
U54 · FY2019 · CA · contact PI
The NF-KappaB-Androgen Receptor Axis Drives Failure of Medical Therapy in Human Benign Prostatic Hyperplasia$410,086
R01 · FY2018 · DK · contact PI
Novel mechanisms of SKP2 and AR signaling on the suppression of prostate cancer$98,741
U54 · FY2018 · CA · contact PI
Novel mechanisms of SKP2 and AR signaling on the suppression of prostate cancer$11,556
U54 · FY2018 · CA · contact PI
The NF-KappaB-Androgen Receptor Axis Drives Failure of Medical Therapy in Human Benign Prostatic Hyperplasia$410,086
R01 · FY2017 · DK · contact PI
Novel mechanisms of SKP2 and AR signaling on the suppression of prostate cancer$99,997
U54 · FY2017 · CA · contact PI
The NF-KappaB-Androgen Receptor Axis Drives Failure of Medical Therapy in Human Benign Prostatic Hyperplasia$424,586
R01 · FY2016 · DK · contact PI
Novel mechanisms of SKP2 and AR signaling on the suppression of prostate cancer$101,120
U54 · FY2016 · CA · contact PI
Molecular Mechanisms of SKP2 Targeting on Prostate Cancer Progression$8,321
U54 · FY2014 · CA · contact PI
Control of Prostate-Specific Gene Expression$320,909
R01 · FY2013 · DK · contact PI
Molecular Mechanisms of SKP2 Targeting on Prostate Cancer Progression$67,987
U54 · FY2013 · CA · contact PI
Transgenic Animal Models for Prostate Cancer$405,422
R01 · FY2012 · CA · contact PI
Control of Prostate-Specific Gene Expression$332,548
R01 · FY2012 · DK · contact PI
Molecular Mechanisms of SKP2 Targeting on Prostate Cancer Progression$73,314
U54 · FY2012 · CA · contact PI
Transgenic Animal Models for Prostate Cancer$406,161
R01 · FY2011 · CA · contact PI
Control of Prostate-Specific Gene Expression$332,015
R01 · FY2011 · DK · contact PI
Molecular Mechanisms of SKP2 Targeting on Prostate Cancer Progression$73,925
U54 · FY2011 · CA · contact PI
Transgenic Animal Models for Prostate Cancer$431,377
R01 · FY2010 · CA · contact PI
Control of Prostate-Specific Gene Expression$368,280
R01 · FY2010 · DK · contact PI
Transgenic Animal Models for Prostate Cancer$426,814
R01 · FY2009 · CA · contact PI
Control of Prostate-Specific Gene Expression$371,100
R01 · FY2009 · DK · contact PI
Control of Prostate-Specific Gene Expression$21,086
R01 · FY2009 · DK · contact PI
Transgenic Animal Models for Prostate Cancer$445,093
R01 · FY2007 · CA · contact PI
Control of Prostate-Specific Gene Expression$302,817
R01 · FY2007 · DK · contact PI
Transgenic Animal Models for Prostate Cancer$463,937
R01 · FY2006 · CA · contact PI
Control of Prostate-Specific Gene Expression$311,860
R01 · FY2006 · DK · contact PI
Control of Prostate Growth and Tumor Progression$258,041
R01 · FY2006 · AG · contact PI
Transgenic Animal Models for Prostate Cancer$354,850
R01 · FY2005 · CA
Control of Prostate-Specific Gene Expression$319,365
R01 · FY2005 · DK
Control of Prostate Growth and Tumor Progression$302,000
R01 · FY2005 · AG
Transgenic Animal Models for Prostate Cancer$354,850
R01 · FY2004 · CA
Control of Prostate-Specific Gene Expression$319,365
R01 · FY2004 · DK
Control of Prostate Growth and Tumor Progression$264,250
R01 · FY2004 · AG
Control of Prostate Growth and Tumor Progression$37,750
R01 · FY2004 · AG
Transgenic Animal Models for Prostate Cancer$354,850
R01 · FY2003 · CA
Control of Prostate-Specific Gene Expression$319,365
R01 · FY2003 · DK
Control of Prostate Growth and Tumor Progression$264,250
R01 · FY2003 · AG
TRANSGENIC MOUSE MODEL FOR PROSTATE CANCER$387,477
R01 · FY2002 · CA
CONTROL OF PROSTATE-SPECIFIC GENE EXPRESSION$266,275
R01 · FY2002 · DK
TRANSGENIC MOUSE MODEL FOR PROSTATE CANCER$377,567
R01 · FY2001 · CA
CONTROL OF PROSTATE-SPECIFIC GENE EXPRESSION$261,201
R01 · FY2001 · DK
TRANSGENIC MOUSE MODEL FOR PROSTATE CANCER$367,682
R01 · FY2000 · CA
CONTROL OF PROSTATE-SPECIFIC GENE EXPRESSION$256,415
R01 · FY2000 · DK